Daftar ini adalah analisis berdasarkan peristiwa pasar terbaru. Ini bukan rekomendasi investasi.
Acticor Biotech SAS operates as a clinical stage biopharmaceutical company that develops drugs for the treatment for acute thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets platelet glycoprotein VI. It's product glenzocimab is in Phase 2/3 clinical trial, as well as completed Phase 1b/2a for the treatment of acute ischemic stroke; and Phase 2/3 clinical trial for treatment of cerebrovascular accidents in emergency situations, as well as completed Phase 2 clinical trial for treating acute respiratory distress syndrome (covid-19). The company has collaboration agreement with the University of Birmingham for Phase 2b clinical trials of glenzocimab in treating heart attacks. The company was incorporated in 2013 and is headquartered in Paris, France.
Show more...
FAQ
Apa simbol saham Acticor Biotech?▼
Tergantung pada bursa, simbol saham dapat berbeda. Misalnya, di bursa Boerse Stuttgart, saham Acticor Biotech diperdagangkan dengan simbol 7V7.STU.
Berapa jumlah karyawan Acticor Biotech?▼
Per September 05, 2026, perusahaan memiliki 31 karyawan.
Acticor Biotech berada di sektor apa?▼
Acticor Biotech beroperasi di sektor Kesehatan & Kebugaran.
Kapan Acticor Biotech menyelesaikan split saham?▼
Acticor Biotech belum melakukan split saham baru-baru ini.
Di mana kantor pusat Acticor Biotech?▼
Kantor pusat Acticor Biotech berlokasi di Paris, Prancis.